Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Kennedy Trust has announced Dr Stephen Simpson as its new Chief Executive Officer from 1 July 2022.

Dr Stephen Simpson and Pierre Espinasse
Dr Stephen Simpson (L) has taken over the role of CEO from Pierre Espinasse (R)

Stephen has taken over the leadership of the Trust from Pierre Espinasse who managed operations at the charity since 2011. The Trust has evolved considerably under Pierre's expert guidance, most notably through its support of the Kennedy Institute's relocation from Imperial College London to its current site at the heart of the University of Oxford's Old Road Campus.

Pierre has also overseen significant funding and support initiatives at the Kennedy Institute including a pledge of £20M over five years to support pioneering research into chronic inflammatory disease, and funding to establish the Career Development Programme, enabling early career researchers to take the first step in running their own lab. The Kennedy Institute also benefits from some of the Trust's key external funding initiatives, spearheaded by Pierre, including the £2.5M Senior Research Fellowship programme launched in 2017 and the MB PhD scheme which will provide funding for 75 students over 7 years across the universities of Manchester, Birmingham, Oxford, Glasgow and Edinburgh.

Professor Dame Fiona Powrie, Director of the Kennedy Institute, added "Pierre has provided vital support to the Kennedy Institute for more than a decade. We wish him all the best for the future, and we look forward to continuing our close relationship with the Kennedy Trust under the expert leadership of Stephen Simpson."

Stephen joins the Trust with a background in medical research and in life sciences research funding. Most recently, Stephen was Director of Research at Versus Arthritis, where he led teams in the development and implementation of research, including new areas of research translation and partnership funding. During his time at the charity, Stephen championed the development of musculoskeletal research through the creation of new funding initiatives and the promotion of pain research and patient involvement.

See more on the Kennedy Trust website

Similar stories

£1.2M to improve diagnosis of emergency spinal condition

The National Institute for Health and Care Research has awarded an Advanced Fellowship to Dr David Metcalfe to study the diagnosis of the spinal condition, cauda equina syndrome.

Professor Chris Lavy appointed to WHO technical advisory group

Congratulations to Professor Chris Lavy, who has been appointed to the World Health Organization’s (WHO) technical advisory group for integrated clinical care for a period of two years.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.

Gene variant links trigger finger and carpal tunnel syndrome

A new NDORMS study, published in The Lancet Rheumatology, has found a genetic variant that increases the risk of both carpal tunnel syndrome and trigger finger, and opens the door for new therapies that involve blocking the IGF-1 pathway.

Kennedy programmes support early career researchers

Since 2013 the Kennedy Institute of Rheumatology has been running a Career Development Programme, a scheme to help early career researchers launch their own independent laboratories, and more recently the Innovator Investigator Programme to bring new technologies to core research themes.

OCTRU collaboration boosts understanding of COVID vaccine response

Working with researchers across multiple universities, the Oxford Clinical Trials Unit (OCTRU) played a key role in delivering results of the national VROOM trial (Vaccine Response On Off Methotrexate).